Thomas Insel, M.D.
Former Director, National Institute of Mental Health (NIMH); Author
Former 13-year NIMH director who, after leaving, became a major voice arguing that conventional psychiatry has failed patients — and that psychedelic therapies may represent the paradigm shift mental health urgently needs.
Biography
Thomas Insel directed the National Institute of Mental Health from 2002 to 2015, overseeing $20 billion in research spending and shaping the federal government's approach to mental health science for over a decade. After leaving NIMH, he led mental health efforts at Google's parent company Verily and co-founded a mental health technology startup before returning to policy advocacy.
In 2022, Insel published Healing: Our Path from Mental Illness to Mental Health, a candid reckoning with the limits of conventional psychiatry. Despite the enormous research investments of his tenure at NIMH, he concluded that the mental health crisis had not improved — and argued that the medical establishment's focus on pharmacology and biological reductionism had come at the cost of neglecting the social, relational, and community dimensions of mental health. The book was widely read and generated significant discussion within psychiatry.
Insel has been increasingly vocal about psychedelic therapies as one of the most promising areas for genuine paradigm change in mental health treatment. His endorsement carries particular weight precisely because of his institutional credibility: having led NIMH for 13 years, his assessment that conventional approaches have failed and that psychedelic-assisted therapy deserves serious attention cannot be dismissed as advocacy from outside the mainstream.
He has spoken and written about psilocybin's evidence base for depression, the FDA pathway for psychedelic-assisted therapies, and the need for mental health systems to think beyond diagnosis and pharmacology to the full ecological context of human suffering.
Organizations
Why They Matter to the LearnShrooms Community
Insel's institutional legitimacy — built on 13 years as NIMH director — gives his endorsement of psychedelic therapy as a promising paradigm shift enormous credibility with the medical and policy establishment. His critique of conventional psychiatry, coming from its former federal director, creates space for the psychedelic research renaissance to be taken seriously by gatekeepers who would dismiss advocacy from outside the mainstream.
Legal Context
For the legal landscape where Thomas Insel, M.D. operates, see psilocybin laws in California.